Another reminder to never, ever hold through data.

I exited my main position last night at 110 after I saw the PR hit the wire.

I thought the data looked good (at least reading it the way they presented it).  Only thing that bothered me was how strange (like a kid's science project) the press release looked (arrows didn't line up...and it was just...arrows? no numbers?), which is what pushed me to sell.

I did hold overnight a smaller position in another account that I kept "just in case" the data was as good as it looked.  

I was wrong and took a hit on that position, sold for a loss today at $50 (from $120) 

The shareholders seem to praise the data and ANVS seemed happy about it, but it was trashed by the market and biotech analysts.  One even called it a "zero."

Not sure it's a zero, but they do need to add more patients, which they're doing in the next phase of the trial.

One potential upside:  They do have an FDA decision coming up next month on an application they made for Orphan Drug designation - irpages2.eqs.com/websites/anno...